CHEK - Check-Cap Ltd.
| Previous Close | 2.0600 |
| Open | 2.0500 |
| Bid | 2.1100 x 1800 |
| Ask | 2.1200 x 1300 |
| Day's Range | 2.0500 - 2.1394 |
| 52 Week Range | 1.2800 - 4.2000 |
| Volume | 50,772 |
| Avg. Volume | 70,419 |
| Market Cap | 17.441M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8110 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- PR Newswire
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive results from the Company's pilot study of the C-Scan® System in the U.S.
- Insider Monkey
Is Check-Cap Ltd. (CHEK) Going To Burn These Hedge Funds ?
How do we determine whether Check-Cap Ltd. (NASDAQ:CHEK) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
- PR Newswire
Check-Cap Announces $4.75 Million Private Placement
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company has entered into definitive agreements with certain investors to purchase approximately $4.75 million of its ordinary shares in a private placement.
- Simply Wall St.
What Kind Of Shareholder Owns Most Check-Cap Ltd. (NASDAQ:CHEK) Stock?
The big shareholder groups in Check-Cap Ltd. (NASDAQ:CHEK) have power over the company. Institutions will often hold...
- PR Newswire
Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights
Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Nov. 6, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" ...
- PR Newswire
Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference
ISFIYA, Israel , Oct. 24, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...
- PR Newswire
Check-Cap Expands Leadership Team With Appointment of Dr. Vardit Segal as Vice President of Clinical Affairs
ISFIYA, Israel , Sept. 25, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics ...
- PR Newswire
Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference
ISFIYA, Israel , Sept. 3, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...
- PR Newswire
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S. ISFIYA, Israel , Aug. 19, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") ...
- PR Newswire
Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights
Reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Aug. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...
- PR Newswire
Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System
ISFIYA, Israel, July 9, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system. The study included 90 evaluable patients who either had known polyps or were considered to be of average risk.
- PR Newswire
Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations
Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics ISFIYA, Israel , June 3, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" ...
- PR Newswire
Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection
ISFIYA, Israel , May 16, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...
- PR Newswire
Check-Cap Reports First Quarter 2019 Financial Results
Initiates U.S. pilot study of C-Scan® at NYU School of Medicine and Mayo Clinic ISFIYA, Israel , May 13, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...
- PR Newswire
Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®
Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S. ISFIYA, Israel, May 13, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that Mayo Clinic is the second trial site participating in the Company's ongoing pilot study of the C-Scan® system in the U.S.
- PR Newswire
Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening
ISFIYA, Israel, April 8, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the initiation of its U.S. pilot study of the C-Scan® system, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested the C-Scan® capsule at the New York University School of Medicine. "The pilot study initiation is a critical milestone on our path for developing and potentially commercializing the C-Scan® system in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.
- PR Newswire
Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results
ISFIYA, Israel , March 28, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...
- PR Newswire
Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer
ISFIYA, Israel , March 18, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (Nasdaq: CHEK) (Nasdaq: CHEKW), (Nasdaq: CHEKZ), a clinical stage medical diagnostics company ...
- PR Newswire
Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®
ISFIYA, Israel, Feb. 12, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW), (CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced it has received Institutional Review Board (IRB) approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system. "We are excited to receive IRB approval as this important milestone enables Check-Cap to bring the C-Scan® system into the clinic in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.
- PR Newswire
Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering
ISFIYA, Israel, Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit. Each unit consisted of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.
- PR Newswire
Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering
ISFIYA, Israel, Feb. 4, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit, in a registered direct offering. Each unit consists of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.
